Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Buy Rating from HC Wainwright

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 476.37% from the stock’s current price. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.67) EPS and Q4 2025 earnings at ($0.68) EPS.

Several other equities research analysts also recently commented on ZNTL. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research report on Monday, August 12th. Oppenheimer restated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Zentalis Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Trading Down 12.2 %

ZNTL opened at $3.47 on Friday. The business’s 50 day moving average is $3.42 and its 200-day moving average is $5.42. The stock has a market cap of $247.27 million, a PE ratio of -1.39 and a beta of 1.74. Zentalis Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, analysts forecast that Zentalis Pharmaceuticals will post -2.81 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. ProShare Advisors LLC lifted its stake in shares of Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock worth $243,000 after buying an additional 1,274 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Zentalis Pharmaceuticals by 20.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after acquiring an additional 585,644 shares during the period. Kennedy Capital Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at about $189,000. Opaleye Management Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the 1st quarter worth about $3,152,000. Finally, SG Americas Securities LLC bought a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at approximately $58,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.